|
Greece Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Greece Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Greece.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Greek pharmaceutical and healthcare industry.
Competitive intelligence, Greek pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Greek market.
The Greece Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Greece Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Greek pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Greece to test other views – a key input for successful budgeting and strategic business planning in the Greek pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Greek Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Greece.
- Exploit The Latest Competitive Greek Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Greece.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Greece Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Greece Pharmaceuticals And Healthcare Industry SWOT |
| Greece Political SWOT |
| Greece Economic SWOT |
| Greece Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Rating |
| Table: Central And Eastern Europe Pharmaceutical And Healthcare Business Environment Ranking For Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Greece – Market Summary |
| Regulatory Regime |
| Intellectual Property Regime |
| Pricing Regime |
| Table: Pharmaceutical Pricing In Greece |
| Reimbursement Regime |
| Parallel Trade |
Chapter - Industry Developments |
| Epidemiology |
| Table: Disease Burden In CEE |
| Healthcare System |
| Secondary Care |
| Recent Healthcare Provision Developments |
| Healthcare Expenditure |
| Healthcare Reforms |
| Research and Development |
| Pharmaceutical Industry |
| Wholesale And Retail Sectors |
| Recent Pharmaceutical Industry Developments |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Greece – Drug Expenditure Indicators, 2004-2013 (EURmn unless otherwise stated) |
| Key Growth Factors – Industry |
| Table: Greece – Health Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Greece - Economic Activity |
| Prescription Market Forecast |
| Table: Greece – Prescription Market Indicators, 2004-2013 (EURmn unless otherwise stated) |
| OTC Market Forecast |
| Patented Market Forecast |
| Table: Greece – Patented Drugs Market Indicators, 2004-2013 |
| Generic Drug Market Forecast |
| Table: Greece – Generics Market Indicators, 2004-2013 |
| Export/Import Forecast |
| Table: Greece – Pharmaceuticals Exports And Imports Indicators, 2004-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Greece – Other Healthcare Data Forecasts, 2004-2013 |
| Key Risks To BMI Forecasts |
Chapter - Competitive Landscape |
| Table: Top 10 Pharmaceutical Companies In Greece By Sales, 2006 |
Chapter - Company Monitor |
| Multinational Company Profiles |
| GlaxoSmithKline |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| Abbott Laboratories |
| Indigenous Company Profiles |
| Vianex |
| Lavipharm |
| Gerolymatos SA |
| Genesis Pharma |
| Genepharm |
| Pharmathen Pharmaceuticals |
| Kleva |
| Alapis Pharma |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Greece Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Pharmaceutical spending in Greece has experienced high levels of growth in recent years, making it the highest spending country per capita in Central and Eastern Europe (CEE). For this reason Greece is positioned top in BMI’s Pharmaceuticals & Healthcare Business Environment Ranking for CEE in Q209, and eighth position globally. Over the next five years, sales of pharmaceuticals, which include prescription drugs and over-the-counter medicines, will increase, albeit at a slower rate, from US$8.43bn to US$10.78bn, representing a compound annual growth rate (CAGR) of 5%.
There are several key macroeconomic, demographic and epidemiological reasons behind our more negative outlook, however, the most pertinent threat to increased spending are the accumulation of debts within the hospital sector. The amount owed to members of the Hellenic Association of Pharmaceutical Companies (SFEE) has spiralled to EUR2.36bn (US$3.23) by most recent estimates. Payment delays have grown to almost two years, a factor which shows considerable risks for pharmaceutical companies. Success in resolving this issue will be a significant determinant of future direction for pharmaceutical policy and represents a significant risk to further growth and Greece’s standing in the Business Environment Rankings. The current political situation may not be conducive to resolving this situation in the short term. A move towards reduced reimbursement could help develop the over-the-counter (OTC) sector over the long term.
In addition to topping our Business Environment Rankings, Greece is also the healthiest country in Central and Eastern Europe according to BMI’s Burden of Disease Database (BoDD). Despite recently being dubbed the heaviest smokers in Europe, healthy Mediterranean diet and lifestyle, in addition to projects such as a recently created model for co-operation in the area of prevention, monitoring and control of endemic and parasitical diseases, limit the number of disability-adjusted life years (DALYs) lost in the country.
Greece’s high per capita spending and reasonably sized population makes it a relatively attractive location to conduct clinical trials. While the country lags behind locations such as Czech Republic, Hungary, Poland and Russia, 115 phase II to IV clinical trials were registered in 2008.
Parallel trade remains prevalent in Greece, thanks to low prices. While prices are not likely to experience any dramatic increases in future, traders’ activities are being increasingly spread to new, low cost bases, such as Romania. Furthermore, the weakening of the sterling has seen a major parallel export market eroded.
|
Greece Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |